D Prieto-Alhambra1, A Judge, N K Arden, C Cooper, K W Lyles, M K Javaid. 1. Oxford NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road, Headington, OX, OX3 7LD, UK.
Abstract
UNLABELLED: Patients with cognitive impairment (CI) often do not receive secondary fracture prevention. Use of zoledronic acid led to a similar reduction in re-fracture risk but the survival benefit was limited to those without CI. INTRODUCTION: We tested whether the effects of zoledronic acid (Zol) on re-fracture and mortality differed in patients presenting with a hip fracture by cognitive status. METHODS: We used data from the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Recurrent Fracture Trial, of yearly intravenous 5 mg Zol vs. placebo in patients presenting with a hip fracture. Primary outcome was new fracture and secondary outcome mortality. Short Portable Mental Status Questionnaire (SPMSQ) with a cut-point of >2 was used to identify CI. Fine-Gray models for competing events were fitted to study the effect of Zol on re-fracture and Cox regression for death. A multiplicative term was introduced to study a potential interaction between treatment and cognitive status on outcomes. RESULTS: Baseline SPMSQ of 1,966/2,127 (92.4%) patients was measured. Three hundred fifty (17.8%) had CI, balanced between treatment arms. In the placebo arm, there was similar fracture incidence between those with and without CI (15.4 vs. 12.3%, p = 0.26). There was no significant interaction for the effect of CI on Zol and re-fracture (p = 0.66). CI was associated with higher 1-year mortality (12.6 vs. 4.3%, p < 0.001) and the interaction was bordering significance (interaction, p = 0.066). Zol prolonged survival only in patients with normal cognitive status [HR 0.56 (95% CI 0.40-0.80)] and not in those with CI [HR 0.90 (95% CI 0.59-1.38)]. CONCLUSIONS: While these results require confirmation, the findings support the use of bisphosphonates in patients with osteoporotic fracture and CI expected to live for more than 6 months.
UNLABELLED: Patients with cognitive impairment (CI) often do not receive secondary fracture prevention. Use of zoledronic acid led to a similar reduction in re-fracture risk but the survival benefit was limited to those without CI. INTRODUCTION: We tested whether the effects of zoledronic acid (Zol) on re-fracture and mortality differed in patients presenting with a hip fracture by cognitive status. METHODS: We used data from the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Recurrent Fracture Trial, of yearly intravenous 5 mg Zol vs. placebo in patients presenting with a hip fracture. Primary outcome was new fracture and secondary outcome mortality. Short Portable Mental Status Questionnaire (SPMSQ) with a cut-point of >2 was used to identify CI. Fine-Gray models for competing events were fitted to study the effect of Zol on re-fracture and Cox regression for death. A multiplicative term was introduced to study a potential interaction between treatment and cognitive status on outcomes. RESULTS: Baseline SPMSQ of 1,966/2,127 (92.4%) patients was measured. Three hundred fifty (17.8%) had CI, balanced between treatment arms. In the placebo arm, there was similar fracture incidence between those with and without CI (15.4 vs. 12.3%, p = 0.26). There was no significant interaction for the effect of CI on Zol and re-fracture (p = 0.66). CI was associated with higher 1-year mortality (12.6 vs. 4.3%, p < 0.001) and the interaction was bordering significance (interaction, p = 0.066). Zol prolonged survival only in patients with normal cognitive status [HR 0.56 (95% CI 0.40-0.80)] and not in those with CI [HR 0.90 (95% CI 0.59-1.38)]. CONCLUSIONS: While these results require confirmation, the findings support the use of bisphosphonates in patients with osteoporotic fracture and CI expected to live for more than 6 months.
Authors: D Marsh; K Akesson; D E Beaton; E R Bogoch; S Boonen; M-L Brandi; A R McLellan; P J Mitchell; J E M Sale; D A Wahl Journal: Osteoporos Int Date: 2011-05-24 Impact factor: 4.507
Authors: B J Gertz; S D Holland; W F Kline; B K Matuszewski; A Freeman; H Quan; K C Lasseter; J C Mucklow; A G Porras Journal: Clin Pharmacol Ther Date: 1995-09 Impact factor: 6.875
Authors: Bradley D Lloyd; Dominique A Williamson; Nalin A Singh; Ross D Hansen; Terrence H Diamond; Terence P Finnegan; Barry J Allen; Jodie N Grady; Theodora M Stavrinos; Emma U R Smith; Ashish D Diwan; Maria A Fiatarone Singh Journal: J Gerontol A Biol Sci Med Sci Date: 2009-03-05 Impact factor: 6.053
Authors: Seoyoung C Kim; Mi-Sook Kim; Gabriel Sanfélix-Gimeno; Hong Ji Song; Jun Liu; Isabel Hurtado; Salvador Peiró; Joongyub Lee; Nam-Kyong Choi; Byung-Joo Park; Jerry Avorn Journal: Am J Med Date: 2015-02-03 Impact factor: 4.965
Authors: Andrew R Zullo; Tingting Zhang; Yoojin Lee; Kevin W McConeghy; Lori A Daiello; Douglas P Kiel; Vincent Mor; Sarah D Berry Journal: J Am Geriatr Soc Date: 2018-12-21 Impact factor: 5.562
Authors: Sarah D Berry; Andrew R Zullo; Yoojin Lee; Vincent Mor; Kevin W McConeghy; Geetanjoli Banerjee; Ralph B D'Agostino; Lori Daiello; David Dosa; Douglas P Kiel Journal: J Gerontol A Biol Sci Med Sci Date: 2018-05-09 Impact factor: 6.053